Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 6/20 | 0.34 |
| ▸ | KDR | P35968 | 6/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.34 |
| ▸ | LCK | P06239 | 5/20 | 0.34 |
| ▸ | FASN | P49327 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24233949 | 1.00 | FFAR1 (0.35) | FFAR1RIPK2KDRTGFBR1LCK | |
| SCHEMBL24365301 | 0.89 | DYRK1A (0.43) | TGFBR1 | |
| SCHEMBL31017209 | 0.81 | FFAR1 (0.36) | FFAR1RIPK2KDRTGFBR1LCK | |
| SCHEMBL30886276 | 0.81 | ALOX5AP (0.33) | FFAR1RIPK2KDRTGFBR1LCK | |
| SCHEMBL24364369 | 0.78 | PIK3CD (0.33) | NOS3NOS1NOS2 | |
| SCHEMBL31145097 | 0.78 | PIK3CD (0.33) | NOS3NOS1NOS2 | |
| SCHEMBL31136351 | 0.77 | SMN1; SMN2 (0.40) | ALDH1A1HSD17B10 | |
| SCHEMBL24363782 | 0.77 | SMN1; SMN2 (0.40) | ALDH1A1HSD17B10 | |
| SCHEMBL24366759 | 0.77 | DYRK1A (0.43) | NOS3NOS1NOS2KDM1A | |
| SCHEMBL24364323 | 0.77 | DYRK1A (0.43) | NOS3NOS1NOS2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11492350-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | FFAR1 1008/4885RIPK2 4321/4885KDR 2938/4885 |
| US-11492350-B2 | Compounds and methods of use | F12, C1R, ABCG2 | FFAR1 1008/4885RIPK2 4321/4885KDR 2938/4885 |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | FFAR1 1008/4885RIPK2 4321/4885KDR 2938/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | FFAR1 1008/4885RIPK2 4321/4885KDR 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.